Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25758606 | 1.00 | CA12 (0.38) | CA12CA9CA1CA2TSHR | |
| SCHEMBL254386 | 0.86 | CA12 (0.42) | CA12CA9CA1CA2TSHR | |
| SCHEMBL11746006 | 0.86 | CA12 (0.42) | CA12CA9CA1CA2TSHR | |
| SCHEMBL2290500 | 0.86 | CA12 (0.42) | CA12CA9CA1CA2TSHR | |
| SCHEMBL11548381 | 0.86 | CA12 (0.42) | CA12CA9CA1CA2TSHR | |
| SCHEMBL11548379 | 0.86 | CA12 (0.42) | CA12CA9CA1CA2TSHR | |
| SCHEMBL23436847 | 0.82 | CA12 (0.38) | CA12CA9CA1CA2TSHR | |
| SCHEMBL25916380 | 0.80 | ALDH1A1 (0.35) | — | |
| SCHEMBL8355844 | 0.78 | CA12 (0.38) | CA12CA9CA1CA2TSHR | |
| SCHEMBL307800 | 0.78 | CA12 (0.38) | CA12CA9CA1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174477-A1 | METHODS FOR SYNTHESIS OF THE TRICYCLIC PROSTAGLANDIN D2 METABOLITE METHYL ESTER | PURDUE RESEARCH FOUNDATION | 2023-06-08 | — | — | US | disclosed |
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | MODERNATX, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180125937-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNATX, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9878056-B2 | Modified polynucleotides for the production of cosmetic proteins and peptides | MODERNATX, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20180002393-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2018-01-04 | — | — | US | disclosed |
| US-20170368200-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-28 | — | — | US | disclosed |
| US-20170348436-A1 | IN VIVO PRODUCTION OF PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-07 | — | — | US | disclosed |
| US-9827332-B2 | Modified polynucleotides for the production of proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828416-B2 | Modified polynucleotides for the production of secreted proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20130237592-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST AT THE SITE OF A CLOT | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130236974-A1 | METHOD FOR INCREASING THE PRODUCTION OF A PROTEIN OF INTEREST | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237593-A1 | MULTI-SITE ADMINISTRATION | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
| US-8304223-B2 | Isoforms of pig liver esterase | ENZYMICALS AG (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20110207186-A1 | Isoforms of Pig Liver Esterase | ENZYMICALS AG (DE) | 2011-08-25 | — | — | US | disclosed |
| US-20100113582-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237593-A1 | MULTI-SITE ADMINISTRATION | PHAX, IGF2BP1, NSUN2 | CA12 2398/4885CA9 3719/4885CA1 3441/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | CA12 3297/4885CA9 2016/4885CA1 4691/4885 |
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | CA12 4804/4885CA9 4809/4885CA1 4862/4885 |
| US-20130236974-A1 | METHOD FOR INCREASING THE PRODUCTION OF A PROTEIN OF INTEREST | IGF2BP1, PHAX, IGF2BP2 | CA12 3283/4885CA9 3805/4885CA1 3851/4885 |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | CA12 4826/4885CA9 4796/4885CA1 4576/4885 |
| US-20180125937-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | CA12 3349/4885CA9 3192/4885CA1 3762/4885 |
| US-20170368200-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | POLRMT, POLN, PHAX | CA12 4728/4885CA9 4783/4885CA1 4770/4885 |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | CA12 3349/4885CA9 3192/4885CA1 3762/4885 |
| US-20130237592-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST AT THE SITE OF A CLOT | TIA1, PAIP1, PHAX | CA12 2933/4885CA9 3538/4885CA1 3477/4885 |
| US-20170348436-A1 | IN VIVO PRODUCTION OF PROTEINS | MSH2, POLRMT, POLN | CA12 4661/4885CA9 4809/4885CA1 4762/4885 |
| US-20230174477-A1 | METHODS FOR SYNTHESIS OF THE TRICYCLIC PROSTAGLANDIN D2 METABOLITE METHYL ESTER | PTGES2, PTGDR2, PTGES | CA12 1162/4885CA9 2746/4885CA1 1990/4885 |
| US-20110207186-A1 | Isoforms of Pig Liver Esterase | CES1, PIGO, PIGS | CA12 3259/4885CA9 2432/4885CA1 2799/4885 |
| US-20100113582-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS | SERPINB1, HPN, PRSS1 | CA12 2604/4885CA9 2429/4885CA1 3327/4885 |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | CA12 4659/4885CA9 4722/4885CA1 4838/4885 |
| US-20180002393-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | MSH2, POLN, MSH6 | CA12 3958/4885CA9 4142/4885CA1 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.